Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ASSESSMENT OF AMLODIPINE ANTIHYPERTENSIVE EFFECT HOMOGENEITY IN CONTROLLED TRIAL

https://doi.org/10.20996/1819-6446-2009-5-2-22-26

Full Text:

Abstract

Aim. To compare influence of amlodipine and spirapril on ambulatory blood pressure profile, including antihypertensive effect smoothness in patients with arterial hypertension (HT).

Methods. 39 patients (aged 53,7±10,0 y.o.) with HT were included in the open, randomized, cross-over study, 30 patients completed study. The duration of every therapies was 4 weeks, initial control period and wash-out period between therapies lasted 1 week. The initial daily dose of amlodipine was 5 mg, standard dose of spirapril (6 mg/daily) was not changed during the trial. After 1-2 weeks of treatment amlodipine dose was increased up to 10 mg/daily as well as dihydrochlorothiazide was added, if necessary. Ambulatory blood pressure monitoring (ABPM) was performed initially and at the end of both therapies.

Results. Both drugs demonstrated good antihypertensive effect according to ABPM data. Decrease of systolic/diastolic blood pressure was 11,2±1,8/7,6±1,2 mm Hg in amlodipine therapy and 10,0±1,8/7,1±1,2 in spirapril therapy (p<0,0001). The smoothness indexes (SI) were 0,65/0,45 and 0,55/0,45, respectively, differences between two therapies were not significant. However the individual analysis of the SI distribution (with SI=0,5 as a satisfactory criterion), showed that antihypertensive effect smoothness is better in amlodipine therapy than this in spirapril one.

Conclusion. Amlodipine has prominent as well as smooth antihypertensive effect, that gives it advantages in the long-term antihypertensive therapy.

About the Authors

V. M. Gorbunov
State Research Center for Preventive Medicine of Rosmedtechnology
Russian Federation

Petroverigsky per. 10, Moscow, 101990



M. I. Smirnova
State Research Center for Preventive Medicine of Rosmedtechnology
Russian Federation

Petroverigsky per. 10, Moscow, 101990



A. D. Deev
State Research Center for Preventive Medicine of Rosmedtechnology
Russian Federation

Petroverigsky per. 10, Moscow, 101990



References

1. Staessen J., Buttebier G., Buntinx F. et al. for the Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. JAMA 1997;278:1065-72.

2. Горбунов В.М., Смирнова М.И., Андреева Г.Ф., и др. Распространенность и предикторы скрытой неэффективности лечения артериальной гипертонии при использовании различных препаратов. Кардиология 2009;49(2):32-7.

3. Palatini P., Parati G. Modulation of 24-h blood pressure profiles: a new target for treatment? J Hypertens 2005;23:1799-801.

4. Kario K. Early morning risk management in hypertension. Current Medicine Group Ltd., 2005.

5. Горбунов В.М., Смирнова М.И., Андреева Г.Ф., Деев А.Д. Влияние спираприла на показатели клинического и амбулаторного артериального давления и их соотношение у больных артериальной гипертонией. Российский кардиологический журнал 2009;(1):57-61.

6. Rizzoni D., Castellano M., Muiesan M.L. et al. Beyond trough:peak ratio: a new index of the smoothness of the antihypertensive effect of a drug. High Blood Press 1997;6:110-5.

7. SAS User`s Guide: Statistics Version 5 Edition. Cary NC:SAS Institute Inc., 1985.

8. Zuther P., Witte K., Lemmer B. АВРМ-FIT and CV-SORT: an easy-to-use software package for detailed analysis of data from ambulatory blood pressure monitoring. Blood Press Monit 1996;1:347-54.

9. Горбунов В.М. Проблемы оценки эффективности антигипертензивной терапии с помощью суточного мониторирования артериального давления. Кардиология. 2003;43(10):105-12.

10. Parati G., Omboni S., Rizzoni D. et al. Smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 1998;16:1685- 91.

11. Rizzoni D., Mueisan M.L., Salvetti M. et al. The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment. J Hypertens 2001;19:703-11.

12. Ruzicka M., Leenen F.H. Relevance of 24 hour blood pressure profile and sympathetic activity for outcome on short- versus long-acting 1,4-dihydropyridines. Am J Hypertens 1996;9:86-94.

13. Palatini P., Malacco E., Di S.S. et al. Trough:peak ratio and smoothness index in the evaluation of 24-h blood presuure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine. Eur J Clin Pharmacol 2002;57(11):765-70.

14. Марцевич С.Ю., Кутишенко Н.П., Дмитриева Н.А., Белолипецкая В.Г. Проблема выбора лекарственного препарата в кардиологии. На что должен ориентироваться практический врач? Кардиоваскулярная терапия и профилактика 2004;(4):77-82.

15. Parati G. Blood pressure variability: its measurement and significance in hypertension. J Hypertens Suppl 2005;23(1):S19-25.


For citation:


Gorbunov V.M., Smirnova M.I., Deev A.D. ASSESSMENT OF AMLODIPINE ANTIHYPERTENSIVE EFFECT HOMOGENEITY IN CONTROLLED TRIAL. Rational Pharmacotherapy in Cardiology. 2009;5(2):22-26. (In Russ.) https://doi.org/10.20996/1819-6446-2009-5-2-22-26

Views: 550


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)